The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, «4-in-1» fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. This combination treatment has been developed by Cipla Limited and the not-for-profit Drugs for Neglected Diseases initiative (DNDi).
Child-friendly 4-in-1 antiretroviral treatment launched for young children living with HIV in South Africa
The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, "4-in-1" fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. This combination treatment has been developed by Cipla Limited and the not-for-profit Drugs for Neglected Diseases initiative (DNDi).